Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 8/20 | 0.77 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3043169 | 0.88 | LTA4H (0.77) | LTA4HHRH3FAAH | |
| SCHEMBL5312794 | 0.87 | LTA4H (1.00) | LTA4HLMNAMEN1ALDH1A1GLA | |
| SCHEMBL5317908 | 0.84 | LTA4H (1.00) | LTA4HFAAHLMNAMEN1ALDH1A1 | |
| SCHEMBL5663496 | 0.83 | LTA4H (0.60) | LTA4HHRH3FAAH | |
| SCHEMBL5312878 | 0.82 | LTA4H (0.59) | LTA4HHRH3FAAHMEN1ALDH1A1 | |
| SCHEMBL3036958 | 0.82 | LTA4H (0.69) | LTA4HHRH3FAAH | |
| SCHEMBL3035819 | 0.81 | LTA4H (0.68) | LTA4HHRH3FAAH | |
| SCHEMBL5657184 | 0.81 | LTA4H (0.57) | LTA4HHRH3FAAH | |
| SCHEMBL5310549 | 0.81 | LTA4H (0.62) | LTA4HHRH3FAAHLMNAALDH1A1 | |
| SCHEMBL5659713 | 0.80 | LTA4H (0.86) | LTA4HHRH3LMNAMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007079003-A2 | AMIDE INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155727-A1 | Amide inhibitors of leukotriene A4 hydrolase | SCHERING AKTIENGESSELLSCHAFT (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155727-A1 | Amide inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885CA1 2812/4885CA2 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.